MyFinsight

HomeBlogAboutContact

MyFinsight

Making company financials insightful for everyone

  • About
  • Blog
  • Privacy Policy
  • Contact

Follow Us

  • X.com
  • Thread
  • Instagram

© 2026 MyFinsight. All rights reserved.

|||

Income Overview

Revenue
$1,294K
Net Income
-$18,331K
Net Profit Margin
-1416.62%
EPS
-$0.32
Unit: Thousand (K) dollars

Income Statement
2026-03-31
2025-12-31
2025-09-30
2025-06-30
Research and collaboration revenue
1,294 348 795 1,497
Research and development
10,160 8,357 9,356 10,343
General and administrative
4,205 4,767 4,596 4,182
Impairment of right-of-use asset
NaN 0 494 NaN
Total operating expenses
14,365 13,124 14,446 14,525
Loss from operations
-13,071 -12,776 -13,651 -13,028
Interest income
910 710 423 453
Change in fair value of derivative tranche liability
-6,188 -28,170* -1,800 NaN
Other expense
NaN 48* NaN NaN
Other income
18 NaN -71 -12
Total other (expense) income, net
-5,260 -27,508 -1,448 441
Net loss attributable to common stockholders
-18,331 -40,284 -15,099 -12,587
Other comprehensive income (loss)
0 0 NaN NaN
Total comprehensive loss
-18,331 -40,284 -15,099 -12,587
Basic EPS
-0.32 -0.747 -0.55 -0.62
Diluted EPS
-0.32 -0.747 -0.55 -0.62
Basic Average Shares
57,923,674 53,935,009 27,274,721 20,159,666
Diluted Average Shares
57,923,674 53,935,009 27,274,721 20,159,666
Unit: Thousand (K) dollars (except for numbers of shares and EPS). Numbers labeled with * are estimated quarterly values.

Time Plot

Show the time plot by selecting a row from the table.

Income Statement

Total comprehensiveloss-$18,331K (-47.44%↓ Y/Y)Net lossattributable to common...-$18,331K (-47.44%↓ Y/Y)Loss from operations-$13,071K (0.22%↑ Y/Y)Total other (expense)income, net-$5,260K (-888.61%↓ Y/Y)Research andcollaboration revenue$1,294K (50.82%↑ Y/Y)Interest income$910K (54.76%↑ Y/Y)Other income$18K (-77.22%↓ Y/Y)Total operatingexpenses$14,365K (2.92%↑ Y/Y)Change in fair value ofderivative tranche...-$6,188K Research and development$10,160K (0.14%↑ Y/Y)General andadministrative$4,205K (10.31%↑ Y/Y)

Camp4 Therapeutics Corp (CAMP)

Camp4 Therapeutics Corp (CAMP)